Perceptive Advisors LLC boosted its stake in Assembly Biosciences Inc (NASDAQ:ASMB) by 21.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 536,626 shares of the biopharmaceutical company’s stock after acquiring an additional 94,793 shares during the period. Perceptive Advisors LLC owned 2.67% of Assembly Biosciences worth $24,282,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Teacher Retirement System of Texas bought a new stake in Assembly Biosciences in the fourth quarter worth about $242,000. Nationwide Fund Advisors bought a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $161,000. Virtus Fund Advisers LLC bought a new stake in shares of Assembly Biosciences in the fourth quarter valued at approximately $361,000. Parametric Portfolio Associates LLC raised its position in shares of Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares during the period. Finally, Wells Fargo & Company MN bought a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $213,000. 77.26% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on the stock. ValuEngine raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 3rd. B. Riley assumed coverage on shares of Assembly Biosciences in a research report on Friday, January 5th. They issued a “neutral” rating and a $35.00 price target on the stock. Jefferies Group boosted their price target on shares of Assembly Biosciences to $75.00 and gave the company a “buy” rating in a research report on Thursday. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Finally, Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a research report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. Assembly Biosciences presently has an average rating of “Buy” and an average price target of $45.50.
Shares of Assembly Biosciences Inc (NASDAQ:ASMB) opened at $58.14 on Monday. Assembly Biosciences Inc has a 12-month low of $18.60 and a 12-month high of $59.94. The stock has a market cap of $1,177.41, a P/E ratio of -19.58 and a beta of 0.57.
COPYRIGHT VIOLATION WARNING: “Perceptive Advisors LLC Increases Holdings in Assembly Biosciences Inc (ASMB)” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-increases-holdings-in-assembly-biosciences-inc-asmb.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.